- Home
- EXAS vs PCVX Comparison
EXAS vs PCVX Comparison
Compare EXAS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- PCVX
- Stock Information
- Founded
- EXAS 1995
- PCVX 2013
- Country
- EXAS United States
- PCVX United States
- Employees
- EXAS N/A
- PCVX N/A
- Industry
- EXAS Medical Specialities
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- EXAS Health Care
- PCVX Health Care
- Exchange
- EXAS Nasdaq
- PCVX Nasdaq
- Market Cap
- EXAS 10.7B
- PCVX 4.4B
- IPO Year
- EXAS N/A
- PCVX 2020
- Fundamental
- Price
- EXAS $51.91
- PCVX $35.76
- Analyst Decision
- EXAS Strong Buy
- PCVX Strong Buy
- Analyst Count
- EXAS 20
- PCVX 10
- Target Price
- EXAS $70.26
- PCVX $136.50
- AVG Volume (30 Days)
- EXAS 2.8M
- PCVX 1.5M
- Earning Date
- EXAS 07-30-2025
- PCVX 08-05-2025
- Dividend Yield
- EXAS N/A
- PCVX N/A
- EPS Growth
- EXAS N/A
- PCVX N/A
- EPS
- EXAS N/A
- PCVX N/A
- Revenue
- EXAS $2,828,128,000.00
- PCVX N/A
- Revenue This Year
- EXAS $14.58
- PCVX N/A
- Revenue Next Year
- EXAS $12.75
- PCVX N/A
- P/E Ratio
- EXAS N/A
- PCVX N/A
- Revenue Growth
- EXAS 11.57
- PCVX N/A
- 52 Week Low
- EXAS $39.97
- PCVX $27.66
- 52 Week High
- EXAS $72.83
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- EXAS 44.34
- PCVX 57.77
- Support Level
- EXAS $52.00
- PCVX $31.79
- Resistance Level
- EXAS $55.90
- PCVX $36.89
- Average True Range (ATR)
- EXAS 2.31
- PCVX 1.51
- MACD
- EXAS -0.04
- PCVX 0.37
- Stochastic Oscillator
- EXAS 24.90
- PCVX 77.65
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.